{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:47:02Z","timestamp":1785498422263,"version":"3.56.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1245\/s10434-025-17650-w","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:00:55Z","timestamp":1751277655000},"page":"6589-6603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["ASO Practice Guideline Series: Management of Colorectal Peritoneal Metastases"],"prefix":"10.1245","volume":"32","author":[{"given":"Michael M.","family":"Wach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2012-2238","authenticated-orcid":false,"given":"Sean P.","family":"Dineen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"issue":"27","key":"17650_CR1","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3748\/wjg.v25.i27.3484","volume":"25","author":"JM Sanchez-Hidalgo","year":"2019","unstructured":"Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Arjona-Sanchez A, et al. Colorectal peritoneal metastases: optimal management review. World J Gastroenterol. 2019;25(27):3484\u2013502.","journal-title":"World J Gastroenterol."},{"issue":"12","key":"17650_CR2","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","volume":"89","author":"DG Jayne","year":"2002","unstructured":"Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545\u201350.","journal-title":"Br J Surg."},{"issue":"8","key":"17650_CR3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/DCR.0000000000000412","volume":"58","author":"P Quere","year":"2015","unstructured":"Quere P, Facy O, Manfredi S, Jooste V, Faivre J, Lepage C, et al. Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study. Dis Colon Rectum. 2015;58(8):743\u201352.","journal-title":"Dis Colon Rectum."},{"issue":"2","key":"17650_CR4","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/jso.26322","volume":"123","author":"VH Le","year":"2021","unstructured":"Le VH, Thornblade L, Ituarte PHG, Lai LL, Melstrom KA. Metachronous peritoneal metastases following curative resection for colon cancer: understanding risk factors and patterns of recurrence. J Surg Oncol. 2021;123(2):622\u20139.","journal-title":"J Surg Oncol."},{"issue":"12","key":"17650_CR5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","volume":"16","author":"N Keum","year":"2019","unstructured":"Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713\u201332.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"4","key":"17650_CR6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1245\/ASO.2004.08.014","volume":"11","author":"VJ Verwaal","year":"2004","unstructured":"Verwaal VJ, Boot H, Aleman BM, van Tinteren H, Zoetmulder FA. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11(4):375\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"17650_CR7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicenter, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366.","journal-title":"Lancet Oncol."},{"issue":"11","key":"17650_CR8","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/cncr.32874","volume":"126","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of colorectal metastases. Cancer. 2020;126(11):2534\u201340.","journal-title":"Cancer."},{"key":"17650_CR9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17363-0","author":"K Schultz","year":"2025","unstructured":"Schultz K, Bansal V, Wach MM, et al. Consensus guideline for the management of colorectal cancer with peritoneal metastases. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-17363-0.","journal-title":"Ann Surg Oncol."},{"key":"17650_CR10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1245\/s10434-023-14368-5","volume":"31","author":"M Hubner","year":"2023","unstructured":"Hubner M, van Der Speeten K, Govaerts K, et al. 2022 peritoneal surface oncology group international consensus on HIPEC regimens for peritoneal malignancies: colorectal cancer. Ann Surg Oncol. 2023;31:567\u201376.","journal-title":"Ann Surg Oncol."},{"key":"17650_CR11","unstructured":"National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology for colon cancer V1.2025. National Comprehensive Cancer Network. Accessed 5 Feb 2025."},{"issue":"6","key":"17650_CR12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.21037\/jgo.2019.01.36","volume":"10","author":"SY Yang","year":"2019","unstructured":"Yang SY, Kang JH, Kim HS, Han YD, Min BS, Lee KY. Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. J Gastrointest Oncol. 2019;10(6):1251\u201365.","journal-title":"J Gastrointest Oncol."},{"issue":"8","key":"17650_CR13","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1245\/s10434-017-5821-7","volume":"24","author":"MA Schneider","year":"2017","unstructured":"Schneider MA, Eshmuminov D, Lehmann K. Major postoperative complications are a risk factor for impaired survival after CRS\/HIPEC. Ann Surg Oncol. 2017;24(8):2224\u201332.","journal-title":"Ann Surg Oncol."},{"key":"17650_CR14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/CMAR.S119569","volume":"9","author":"GA Simkens","year":"2017","unstructured":"Simkens GA, Rovers KP, Nienhuijs SW, de Hingh IH. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res. 2017;9:259\u201366.","journal-title":"Cancer Manag Res."},{"issue":"3","key":"17650_CR15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/07357907.2012.654871","volume":"30","author":"BLD Br\u00fccher","year":"2012","unstructured":"Br\u00fccher BLD, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, et al. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC\u2014Overview and basics. Cancer Investig. 2012;30(3):209\u201324.","journal-title":"Cancer Investig."},{"issue":"4","key":"17650_CR16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/cncr.34567","volume":"129","author":"HDD Witmer","year":"2023","unstructured":"Witmer HDD, Dhiman A, Turaga KK. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: where do we stand? Cancer. 2023;129(4):495\u2013502.","journal-title":"Cancer."},{"issue":"4","key":"17650_CR17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jviscsurg.2018.01.002","volume":"155","author":"A Dohan","year":"2018","unstructured":"Dohan A, Hobeika C, Najah H, Pocard M, Rousset P, Eveno C. Preoperative assessment of peritoneal carcinomatosis of colorectal origin. J Visc Surg. 2018;155(4):293\u2013303.","journal-title":"J Visc Surg."},{"issue":"2","key":"17650_CR18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jso.20049","volume":"86","author":"E de Bree","year":"2004","unstructured":"de Bree E, Koops W, Kroger R, van Ruth S, Witkamp AJ, Zoetmulder FA. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86(2):64\u201373.","journal-title":"J Surg Oncol."},{"issue":"3","key":"17650_CR19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.amjsurg.2013.09.021","volume":"207","author":"W Yoon","year":"2014","unstructured":"Yoon W, Alame A, Berri R. Peritoneal surface disease severity score as a predictor of resectability in the treatment of peritoneal surface malignancies. Am J Surg. 2014;207(3):403\u20137.","journal-title":"Am J Surg."},{"issue":"9","key":"17650_CR20","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1245\/s10434-015-4387-5","volume":"22","author":"D Go\u00e9r\u00e9","year":"2015","unstructured":"Go\u00e9r\u00e9 D, Souadka A, Faron M, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22(9):2958\u201364.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"17650_CR21","doi-asserted-by":"crossref","first-page":"107251","DOI":"10.1016\/j.ejso.2023.107251","volume":"50","author":"V Boldrin","year":"2023","unstructured":"Boldrin V, Khaled C, El Asmar A, Kamden L, Sclafani F, Gomez MG, et al. Predictive factors of non-completion of cytoreductive surgery in colorectal peritoneal metastasis. Eur J Surg Oncol. 2023;50(2):107251.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"17650_CR22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2214\/AJR.08.1753","volume":"193","author":"RN Low","year":"2009","unstructured":"Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings\u2013a feasibility study. AJR Am J Roentgenol. 2009;193(2):461\u201370.","journal-title":"AJR Am J Roentgenol."},{"issue":"1","key":"17650_CR23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejso.2019.02.030","volume":"47","author":"RN Low","year":"2021","unstructured":"Low RN, Barone RM, Rousset P. Peritoneal MRI in patients undergoing cytoreductive surgery and HIPEC: history, clinical applications, and implementation. Eur J Surg Oncol. 2021;47(1):65\u201374.","journal-title":"Eur J Surg Oncol."},{"issue":"4","key":"17650_CR24","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1245\/s10434-024-14901-0","volume":"31","author":"MM Wach","year":"2024","unstructured":"Wach MM, et al. Normal CEA levels after neoadjuvant chemotherapy and cytoreduction with hyperthermic intraperitoneal chemoperfusion predict improved survival from colorectal peritoneal metastases. Ann Surg Oncol. 2024;31(4):2391\u2013400.","journal-title":"Ann Surg Oncol."},{"key":"17650_CR25","volume":"6","author":"H Bando","year":"2022","unstructured":"Bando H, et al. Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer. JCO Precis Oncol. 2022;6:e2100535.","journal-title":"JCO Precis Oncol."},{"issue":"4","key":"17650_CR26","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/jso.24911","volume":"117","author":"MA Kozman","year":"2018","unstructured":"Kozman MA, Fisher OM, Rebolledo BJ, et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. J Surg Oncol. 2018;117(4):725\u201336.","journal-title":"J Surg Oncol."},{"key":"17650_CR27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ejca.2020.11.025","volume":"144","author":"RP Jones","year":"2021","unstructured":"Jones RP, Pugh SA, Graham J, Primrose JN, Barriuso J. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer: a systematic review and meta-analysis. Eur J Cancer. 2021;144:368\u201381.","journal-title":"Eur J Cancer."},{"key":"17650_CR28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1245\/s10434-022-12399-y","volume":"30","author":"BG Sullivan","year":"2023","unstructured":"Sullivan BG, Lo A, Yu J, et al. Circulating tumor DNA is unreliable to detect somatic gene alterations in gastrointestinal peritoneal carcinomatosis. Ann Surg Oncol. 2023;30:278\u201384.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"17650_CR29","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1245\/s10434-023-13219-7","volume":"30","author":"PA Vallejos","year":"2023","unstructured":"Vallejos PA, Gonda A, Yu J, et al. Plasma exosome gene signature differentiates colon cancer from healthy controls. Ann Surg Oncol. 2023;30(6):3833\u201344.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"17650_CR30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/SLA.0000000000005856","volume":"278","author":"A Dhiman","year":"2023","unstructured":"Dhiman A, Kothary V, Witmer HDD, et al. Role of tumor-informed personalized ctDNA assay in informing recurrence in patients with peritoneal metastases from colorectal and high-grade appendix cancer undergoing curative intent surgery. Ann Surg. 2023;278(6):925\u201331.","journal-title":"Ann Surg."},{"key":"17650_CR31","volume":"12","author":"L Zeng","year":"2022","unstructured":"Zeng L, et al. Tumor mutational burden associated with response to hyperthermic intraperitoneal chemotherapy. Front Oncol. 2022;12:796263.","journal-title":"Front Oncol."},{"issue":"1","key":"17650_CR32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1245\/s10434-022-12437-9","volume":"30","author":"CT Ong","year":"2023","unstructured":"Ong CT, et al. Insurance authorization barriers in patients undergoing cytoreductive surgery and HIPEC. Ann Surg Oncol. 2023;30(1):417\u201322.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"17650_CR33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1758834013500375","volume":"5","author":"L Howie","year":"2013","unstructured":"Howie L, Peppercorn J. Early palliative care in cancer treatment: rationale, evidence and clinical implications. Ther Adv Med Oncol. 2013;5(6):318\u201323.","journal-title":"Ther Adv Med Oncol."},{"issue":"5","key":"17650_CR34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/SLA.0000000000004326","volume":"272","author":"B Noiret","year":"2020","unstructured":"Noiret B, et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year national French practice. Ann Surg. 2020;272(5):847\u201354.","journal-title":"Ann Surg."},{"issue":"1","key":"17650_CR35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/jso.25939","volume":"122","author":"B Noiret","year":"2020","unstructured":"Noiret B, Clement G, Lenne X, Bruandet A, Glehen O, Voron T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: technical considerations and the learning curve. J Surg Oncol. 2020;122(1):85\u201395.","journal-title":"J Surg Oncol."},{"issue":"1","key":"17650_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12885-020-07756-7","volume":"21","author":"S Zhou","year":"2021","unstructured":"Zhou S, Feng Q, Zhang J, Zhou H, Jiang Z, Liu Z, et al. High-grade postoperative complications affect survival outcomes of patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. BMC Cancer. 2021;21(1):41.","journal-title":"BMC Cancer."},{"issue":"8","key":"17650_CR37","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/jnci\/djab001","volume":"113","author":"E Breuer","year":"2021","unstructured":"Breuer E, Hebeisen M, Schneider MA, Roth L, Pauli C, Frischer-Ordu K, et al. Site of recurrence and survival after surgery for colorectal peritoneal metastasis. J Natl Cancer Inst. 2021;113(8):1027\u201335.","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"17650_CR38","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1245\/s10434-018-6860-4","volume":"26","author":"Y Feferman","year":"2019","unstructured":"Feferman Y, Solomon D, Bhagwandin S, Kim J, Aycart SN, Feingold D, et al. Sites of recurrence after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis from colorectal and appendiceal adenocarcinoma: a tertiary center experience. Ann Surg Oncol. 2019;26(2):482\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"17650_CR39","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1245\/s10434-019-07294-y","volume":"26","author":"JE Hentzen","year":"2019","unstructured":"Hentzen JE, Rovers KP, Kuipers H, van der Plas WY, Been LB, Hoogwater FJ, et al. Impact of synchronous versus metachronous onset of colorectal peritoneal metastases on survival outcomes after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a multicenter, retrospective, observational study. Ann Surg Oncol. 2019;26(7):2210\u201321.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"17650_CR40","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/annonc\/mdu031","volume":"25","author":"AM Kuijpers","year":"2014","unstructured":"Kuijpers AM, Mehta AM, Boot H, Van Leerdam ME, Hauptmann M, Aalbers AG, et al. Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Oncol. 2014;25(4):864\u20139.","journal-title":"Ann Oncol."},{"issue":"5","key":"17650_CR41","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/jso.26792","volume":"125","author":"PH Sugarbaker","year":"2022","unstructured":"Sugarbaker PH, Chang D. Revised prognostic indicators for treatment of lymph node positive colorectal peritoneal metastases. J Surg Oncol. 2022;125(5):889\u2013900.","journal-title":"J Surg Oncol."},{"issue":"12","key":"17650_CR42","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17(12):1709\u201319.","journal-title":"Lancet Oncol."},{"issue":"1","key":"17650_CR43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63\u20138.","journal-title":"J Clin Oncol."},{"issue":"3","key":"17650_CR44","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3390\/jcm9030748","volume":"9","author":"EW Beal","year":"2020","unstructured":"Beal EW, Suarez-Kelly LP, Kimbrough CW, Johnston FM, Greer J, Abbott DE, et al. Impact of neoadjuvant chemotherapy on the outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional retrospective review. J Clin Med. 2020;9(3):748.","journal-title":"J Clin Med."},{"key":"17650_CR45","doi-asserted-by":"crossref","first-page":"101746","DOI":"10.1016\/j.eclinm.2022.101746","volume":"55","author":"PH Cashin","year":"2023","unstructured":"Cashin PH, Esquivel J, Larsen SG, Liauw W, Alzahrani NA, Morris DL, et al. Perioperative chemotherapy in colorectal cancer with peritoneal metastases: a global propensity score matched study. EClinicalMedicine. 2023;55:101746.","journal-title":"EClinicalMedicine."},{"issue":"9","key":"17650_CR46","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1245\/s10434-014-3713-7","volume":"21","author":"W Ceelen","year":"2014","unstructured":"Ceelen W, Van Nieuwenhove Y, Putte DV, Pattyn P. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol. 2014;21(9):3023\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"17650_CR47","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1245\/s10434-016-5214-3","volume":"23","author":"RA Devilee","year":"2016","unstructured":"Devilee RA, Simkens GA, Van Oudheusden TR, Rutten HJ, Creemers GJ, Ten Tije AJ, et al. Increased survival of patients with synchronous colorectal peritoneal metastases receiving preoperative chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2841\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"17650_CR48","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/jso.27136","volume":"127","author":"DN Hanna","year":"2023","unstructured":"Hanna DN, Macfie R, Ghani MO, Hermina A, Mina A, Cha DE, et al. A total neoadjuvant chemotherapy approach is associated with improved recurrence-free survival in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and HIPEC. J Surg Oncol. 2023;127(3):442\u20139.","journal-title":"J Surg Oncol."},{"issue":"3","key":"17650_CR49","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1245\/s10434-015-4914-4","volume":"23","author":"M Maillet","year":"2016","unstructured":"Maillet M, Glehen O, Lambert J, Goere D, Pocard M, Msika S, et al. Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study. Ann Surg Oncol. 2016;23(3):863\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17650_CR50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00384-023-04407-8","volume":"38","author":"K Noda","year":"2023","unstructured":"Noda K, Tominaga T, Nonaka T, Ishii M, Fukuoka H, Hisanaga M, et al. Effect of adjuvant chemotherapy after curative resection of colorectal cancer peritoneal metastasis. Int J Colorectal Dis. 2023;38(1):101.","journal-title":"Int J Colorectal Dis."},{"issue":"7","key":"17650_CR51","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ejso.2021.01.018","volume":"47","author":"DJ Repullo","year":"2021","unstructured":"Repullo DJ, Barbois S, Leonard D, Bohlok A, Van den Audenaeren ET, Hendlisz A, et al. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective analysis. Eur J Surg Oncol. 2021;47(7):1661\u20137.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"17650_CR52","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/DCR.0000000000000774","volume":"60","author":"WJ van Eden","year":"2017","unstructured":"van Eden WJ, Kok NF, J\u00f3\u017awiak K, Lahaye ML, Beets GL, van Leerdam ME, et al. Timing of systemic chemotherapy in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Dis Colon Rectum. 2017;60(5):477\u201387.","journal-title":"Dis Colon Rectum."},{"issue":"8","key":"17650_CR53","doi-asserted-by":"crossref","first-page":"e202701","DOI":"10.1001\/jamaoncol.2020.2701","volume":"6","author":"KP Rovers","year":"2020","unstructured":"Rovers KP, Bakkers C, Van Erning FN, Burger JW, Nienhuijs SW, Simkens GA, et al. Adjuvant systemic chemotherapy vs active surveillance following up-front resection of isolated synchronous colorectal peritoneal metastases. JAMA Oncol. 2020;6(8):e202701.","journal-title":"JAMA Oncol."},{"issue":"8","key":"17650_CR54","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/jamasurg.2021.1642","volume":"156","author":"KP Rovers","year":"2021","unstructured":"Rovers KP, Bakkers C, Nienhuijs SW, Burger JWA, Creemers GM, Thijs AMJ. Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: a phase 2 randomized clinical trial. JAMA Surg. 2021;156(8):710\u201320.","journal-title":"JAMA Surg."},{"key":"17650_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5545-0","volume":"19","author":"KP Rovers","year":"2019","unstructured":"Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer. 2019;19:1\u2013390.","journal-title":"BMC Cancer."},{"issue":"6","key":"17650_CR56","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(17)30336-4","volume":"18","author":"J Tseng","year":"2017","unstructured":"Tseng J, Bryan DS, Poli E, Sharma M, Polite BN, Turaga KK. Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Lancet Oncol. 2017;18(6):711\u20132.","journal-title":"Lancet Oncol."},{"issue":"6","key":"17650_CR57","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1245\/s10434-013-3442-3","volume":"21","author":"C Eveno","year":"2014","unstructured":"Eveno C, Passot G, Go\u00e9r\u00e9 D, Soyer P, Gayat E, Glehen O, et al. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2014;21(6):1792\u2013800.","journal-title":"Ann Surg Oncol."},{"issue":"25","key":"17650_CR58","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1200\/JCO.22.00839","volume":"40","author":"D Rossini","year":"2022","unstructured":"Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, et al. Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS\/BRAF wild-type metastatic colorectal cancer: the phase III TRIPLETE study by GON. J Clin Oncol. 2022;40(25):2878\u201388.","journal-title":"J Clin Oncol"},{"issue":"5","key":"17650_CR59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab versus chemotherapy for microsatellite instability high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23(5):659\u201370.","journal-title":"Lancet Oncol."},{"issue":"5","key":"17650_CR60","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","volume":"27","author":"D Elias","year":"2009","unstructured":"Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681\u20135.","journal-title":"J Clin Oncol."},{"issue":"9","key":"17650_CR61","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332.","journal-title":"Ann Surg Oncol."},{"key":"17650_CR62","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","volume":"257","author":"D Go\u00e9r\u00e9","year":"2013","unstructured":"Go\u00e9r\u00e9 D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257:1065\u201371.","journal-title":"Ann Surg."},{"key":"17650_CR63","first-page":"49","volume":"15","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49\u201358.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"17650_CR64","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1055-3207(03)00048-6","volume":"12","author":"PH Sugarbaker","year":"2003","unstructured":"Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am. 2003;12(3):703\u201327.","journal-title":"Surg Oncol Clin N Am."},{"issue":"Suppl 1","key":"17650_CR65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s13193-022-01593-9","volume":"14","author":"PH Sugarbaker","year":"2023","unstructured":"Sugarbaker PH. Selection factors for treatment and stratification of rare abdominal or pelvic tumors with peritoneal metastases. Indian J Surg Oncol. 2023;14(Suppl 1):7\u201314.","journal-title":"Indian J Surg Oncol."},{"issue":"9","key":"17650_CR66","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/DCR.0000000000001156","volume":"61","author":"D Baratti","year":"2018","unstructured":"Baratti D, Kusamura S, Iusco D, Cotsoglou C, Guaglio M, Battaglia L, et al. Should a history of extraperitoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer peritoneal metastases? Dis Colon Rectum. 2018;61(9):1026\u201334.","journal-title":"Dis Colon Rectum."},{"issue":"3","key":"17650_CR67","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1245\/s10434-021-10925-y","volume":"29","author":"MC Polderdijk","year":"2022","unstructured":"Polderdijk MC, Brouwer M, Haverkamp L, Ziesemer KA, Tenhagen M, Boerma D, et al. Outcomes of combined peritoneal and local treatment for patients with peritoneal and limited liver metastases of colorectal origin: a systematic review and meta-analysis. Ann Surg Oncol. 2022;29(3):1952\u201362.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"17650_CR68","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/codi.14057","volume":"20","author":"MB Bignell","year":"2018","unstructured":"Bignell MB, Mehta AM, Alves S, Chandrakumaran K, Dayal SP, Mohamed F, et al. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer. Colorectal Dis. 2018;20(8):704\u201310.","journal-title":"Colorectal Dis."},{"issue":"2","key":"17650_CR69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275\u201392.","journal-title":"J Pathol."},{"issue":"15","key":"17650_CR70","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.3390\/ijms20153619","volume":"20","author":"P Noordhuis","year":"2019","unstructured":"Noordhuis P, Laan AC, van de Born K, Honeywell RJ, Peters GJ. Coexisting molecular determinants of acquired oxaliplatin resistance in human colorectal and ovarian cancer cell lines. Int J Mol Sci. 2019;20(15):3619.","journal-title":"Int J Mol Sci."},{"key":"17650_CR71","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/1471-2164-14-480","volume":"14","author":"P Virag","year":"2013","unstructured":"Virag P, Fischer-Fodor E, Perde-Schrepler M, et al. Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins. BMC Genom. 2013;14:480.","journal-title":"BMC Genom."},{"issue":"4","key":"17650_CR72","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ejso.2020.09.017","volume":"47","author":"RA Nagourney","year":"2021","unstructured":"Nagourney RA, Evans S, Tran PH, Nagourney AJ, Sugarbaker PH. Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin. Eur J Surg Oncol. 2021;47(4):738\u201342.","journal-title":"Eur J Surg Oncol."},{"issue":"14","key":"17650_CR73","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.18632\/oncotarget.26667","volume":"10","author":"L Lemoine","year":"2019","unstructured":"Lemoine L, Thijssen E, Carleer R, Cops J, Lemmens V, Eyken PV, Sugarbaker P, Speeten KV. Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization. Oncotarget. 2019;10(14):1407\u201324.","journal-title":"Oncotarget."},{"issue":"7","key":"17650_CR74","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.23728","volume":"110","author":"A Prada-Villaverde","year":"2014","unstructured":"Prada-Villaverde A, Esquivel J, Lowy AM, et al. The American society of peritoneal surface malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110(7):779\u201385.","journal-title":"J Surg Oncol."},{"issue":"7","key":"17650_CR75","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","volume":"158","author":"A Arjona-S\u00e1nchez","year":"2023","unstructured":"Arjona-S\u00e1nchez A, Espinosa-Redondo E, Guti\u00e9rrez-Calvo A, Segura-Sampedro JJ, P\u00e9rez-Viejo E, Concepci\u00f3n-Mart\u00edn V, et al. Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: a phase 3 randomized clinical trial. JAMA Surg. 2023;158(7):683\u201391.","journal-title":"JAMA Surg."},{"issue":"5","key":"17650_CR76","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1245\/s10434-014-3976-z","volume":"22","author":"AN Doud","year":"2015","unstructured":"Doud AN, Randle RW, Clark CJ, Levine EA, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22(5):1645\u201350.","journal-title":"Ann Surg Oncol."},{"key":"17650_CR77","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1245\/s10434-024-16188-7","volume":"32","author":"SP Dineen","year":"2025","unstructured":"Dineen SP. Experience is key: considerations of gastrectomy during CRS\/HIPEC for extensive pseudomyxoma peritonei. Ann Surg Oncol. 2025;32:17\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17650_CR78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1245\/s10434-024-15880-y","volume":"32","author":"A Lord","year":"2025","unstructured":"Lord A, Samuel VM, Kung V, et al. Selective gastrectomy with knowledge of gastric anatomy and blood supply are key to complete tumour removal in advanced pseudomyxoma: single-centre experience with 120 gastrectomies over 20 years. Ann Surg Oncol. 2025;32(1):192\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"17650_CR79","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1245\/s10434-024-15863-z","volume":"31","author":"A Gonzalez-Gil","year":"2024","unstructured":"Gonzalez-Gil A, Gomez-Ruiz \u00c1J, Gonzalez-P\u00e9rez C, Gil-Gomez E, Olivares-Ripoll V, Martinez J, Barcel\u00f3 F, Cascales-Campos PA. Systematic cholecystectomy during cytoreductive surgery plus HIPEC: a critical analysis of an empirical tradition. Ann Surg Oncol. 2024;31(10):7157\u201364.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"17650_CR80","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.ejso.2021.02.017","volume":"47","author":"A Brind\u2019Amour","year":"2021","unstructured":"Brind\u2019Amour A, Pravong V, Sid\u00e9ris L, Dub\u00e9 P, De Guerke L, Fortin S, Auclair MH, Trilling B, Tremblay JF. Rectal anastomosis and hyperthermic intraperitoneal chemotherapy: should we avoid diverting loop ileostomy? Eur J Surg Oncol. 2021;47(9):2346\u201351.","journal-title":"Eur J Surg Oncol."},{"issue":"12","key":"17650_CR81","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1016\/j.ejso.2022.05.018","volume":"48","author":"TM Feenstra","year":"2022","unstructured":"Feenstra TM, Verberne CJ, Kok NF, Aalbers AGJ. Anastomotic leakage after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer. Eur J Surg Oncol. 2022;48(12):2460\u20136.","journal-title":"Eur J Surg Oncol."},{"issue":"9","key":"17650_CR82","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.ejso.2021.05.009","volume":"47","author":"VP Bastiaenen","year":"2021","unstructured":"Bastiaenen VP, Aalbers AGJ, Arjona-S\u00e1nchez A, et al. Risk of metachronous peritoneal metastases in patients with pT4a versus pT4b colon cancer: an international multicentre cohort study. Eur J Surg Oncol. 2021;47(9):2405\u201313.","journal-title":"Eur J Surg Oncol."},{"issue":"10","key":"17650_CR83","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","volume":"4","author":"CE Klaver","year":"2019","unstructured":"Klaver CE, Wisselink DD, Punt CJ, Snaebjornsson P, Crezee J, Aalbers AG. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC)z a multicentre, open-label, randomized trial. Lancet Gastroenterol Hepatol. 2019;4(10):761\u201370.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"9","key":"17650_CR84","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","volume":"21","author":"D Go\u00e9r\u00e9","year":"2020","unstructured":"Go\u00e9r\u00e9 D, Glehen O, Quenet F, Guilloit JM, Bereder JM, Lorimier G, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020;21(9):1147\u201354.","journal-title":"Lancet Oncol."},{"issue":"6","key":"17650_CR85","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/jso.23303","volume":"107","author":"YL Klaver","year":"2013","unstructured":"Klaver YL, Chua TC, Verwaal VJ, de Hingh IH, Morris DL. Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction. J Surg Oncol. 2013;107(6):585\u201390.","journal-title":"J Surg Oncol."},{"issue":"2","key":"17650_CR86","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jso.23062","volume":"106","author":"N Golse","year":"2012","unstructured":"Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, et al. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol. 2012;106(2):197\u2013203.","journal-title":"J Surg Oncol."},{"issue":"3","key":"17650_CR87","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jamcollsurg.2012.04.023","volume":"215","author":"KI Votanopoulos","year":"2012","unstructured":"Votanopoulos KI, Ihemelandu C, Shen P, Stewart JH, Russell GB, Levine EA. Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg. 2012;215(3):412\u20137.","journal-title":"J Am Coll Surg."},{"issue":"8","key":"17650_CR88","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/02656736.2014.974693","volume":"30","author":"M Vaira","year":"2014","unstructured":"Vaira M, Robella M, Mellano A, Sottile A, De Simone M. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence. Int J Hyperthermia. 2014;30(8):565\u20139.","journal-title":"Int J Hyperthermia."},{"issue":"10","key":"17650_CR89","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2468-1253(23)00191-7","volume":"8","author":"RS Krouse","year":"2023","unstructured":"Krouse RS, Anderson GL, Arnold KB, et al. Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. Lancet Gastroenterol Hepatol. 2023;8(10):908\u201318.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"17650_CR90","first-page":"727","volume":"17","author":"BD Badgwell","year":"2009","unstructured":"Badgwell BD, Smith K, Liu P, Bruera E, Curley SA, Cormier JN. Indicators of surgery and survival in oncology inpatients requiring surgical evaluation for palliation. Support Care Cancer. 2009;17:727\u201334.","journal-title":"Support Care Cancer"},{"key":"17650_CR91","doi-asserted-by":"crossref","unstructured":"Cousins SE, Tempest E, Feuer DJ. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2016;(1):CD002764ref.","DOI":"10.1002\/14651858.CD002764.pub2"},{"issue":"4","key":"17650_CR92","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/1049909120968249","volume":"38","author":"W Wey","year":"2021","unstructured":"Wey W, Mian M, Calabrese R, et al. Palliative medical management of inoperable malignant bowel obstruction with \u201ctriple therapy\u201d: dexamethasone, octreotide, and metoclopramide. Am J Hosp Palliat Care. 2021;38(4):340\u20135.","journal-title":"Am J Hosp Palliat Care"},{"issue":"2","key":"17650_CR93","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0825859719864915","volume":"35","author":"S Thampy","year":"2020","unstructured":"Thampy S, Najran P, Mullan D, Laasch H-U. Safety and efficacy of venting gastrostomy in malignant bowel obstruction: a systematic review. J Palliat Care. 2020;35(2):93\u2013102.","journal-title":"J Palliat Care"},{"issue":"7","key":"17650_CR94","first-page":"2877","volume":"24","author":"E Zucchi","year":"2016","unstructured":"Zucchi E, Fornasarig M, Martella L, et al. Decompressive percutaneous endoscopic gastrostomy in advanced cancer patients with small-bowel obstruction is feasible and effective: a large prospective study. Support Care Cancer. 2016;24(7):2877\u201382.","journal-title":"Support Care Cancer"},{"issue":"9","key":"17650_CR95","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/CMAR.S100210","volume":"12","author":"M Stukan","year":"2017","unstructured":"Stukan M. Drainage of malignant ascites: patient selection and perspectives. Cancer Manag Res. 2017;12(9):115\u201330.","journal-title":"Cancer Manag Res."},{"issue":"11","key":"17650_CR96","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1245\/s10434-022-12204-w","volume":"29","author":"M Read","year":"2022","unstructured":"Read M, Powers BD, Pimiento JM, et al. Management of malignant small bowel obstruction: is intestinal bypass effective palliation? Ann Surg Oncol. 2022;29(11):6980\u20137.","journal-title":"Ann Surg Oncol."},{"issue":"Suppl 1","key":"17650_CR97","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.21037\/jgo-20-257","volume":"12","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Rovers KP, Nienhuijs SW, Creemers GJ, Burger JW, De Hingh IH. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases: a systematic review. J Gastrointest Oncol. 2021;12(Suppl 1):S242\u201358.","journal-title":"J Gastrointest Oncol."},{"issue":"4","key":"17650_CR98","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/cancers15041125","volume":"15","author":"A Di Giorgio","year":"2023","unstructured":"Di Giorgio A, Macri A, Ferracci F, Robella M, Visaloco M, De Manzoni G, et al. 10 years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis. Cancers (Basel). 2023;15(4):1125.","journal-title":"Cancers (Basel)."},{"issue":"7","key":"17650_CR99","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, Hubner M, Grass F, et al. Pressurized intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368\u201377.","journal-title":"Lancet Oncol."},{"issue":"1","key":"17650_CR100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejso.2019.06.028","volume":"47","author":"M Alyami","year":"2021","unstructured":"Alyami M, Mercier F, Siebert M, et al. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2021;47(1):128\u201333.","journal-title":"Eur J Surg Oncol."},{"issue":"9","key":"17650_CR101","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1245\/s10434-020-09508-0","volume":"28","author":"N Tabchouri","year":"2021","unstructured":"Tabchouri N, Buggisch J, Demtroder CR, et al. Pressurized intraperitoneal aerosol chemotherapy for colorectal peritoneal metastases. Ann Surg Oncol. 2021;28(9):5275\u201386.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"17650_CR102","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1245\/s10434-021-10110-1","volume":"28","author":"AJ Rossi","year":"2021","unstructured":"Rossi AJ, Khan TM, Rehman SU, Nash GM, Hernandez JM. Early postoperative intraperitoneal versus hyperthermic intraperitoneal chemotherapy after optimal cytoreductive surgery for colorectal cancer with isolated peritoneal metastasis (ICARuS). Ann Surg Oncol. 2021;28(8):4100\u20131.","journal-title":"Ann Surg Oncol."},{"key":"17650_CR103","doi-asserted-by":"crossref","unstructured":"Nash GM, Garcia-Aguilar J, Paty P, et al. Colorectal cohort analysis from the intraperitoneal chemotherapy after cytoreductive surgery for peritoneal metastasis (ICARuS) clinical trial. J Clin Oncol. 2023; 41(4).","DOI":"10.1200\/JCO.2023.41.4_suppl.160"},{"issue":"1","key":"17650_CR104","volume":"32","author":"A Sikora","year":"2024","unstructured":"Sikora A, Sullivan KM, Dineen S, Raoof M, Karolak A. Emerging therapeutic approaches for peritoneal metastases from gastrointestinal cancers. Mol Ther Oncol. 2024;32(1):200767.","journal-title":"Mol Ther Oncol."},{"issue":"1","key":"17650_CR105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41598-020-79721-0","volume":"11","author":"D Garc\u00eda-Olmo","year":"2021","unstructured":"Garc\u00eda-Olmo D, Villarejo Campos P, Barambio J, Gomez-Heras SG, Vega-Clemente L, Olmedillas-Lopez S, et al. Intraperitoneal collagenase as a novel therapeutic approach in an experimental model of colorectal peritoneal carcinomatosis. Sci Rep. 2021;11(1):503.","journal-title":"Sci Rep."},{"key":"17650_CR106","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijpharm.2015.10.058","volume":"496","author":"G Kandasamy","year":"2015","unstructured":"Kandasamy G, Maity D. Recent advances in superparamagnetic iron oxide nanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics. Int J Pharm. 2015;496:191\u2013218.","journal-title":"Int J Pharm."},{"key":"17650_CR107","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.3390\/ijms221910522","volume":"22","author":"K Mantwill","year":"2021","unstructured":"Mantwill K, Klein FG, Wang D, Hindupur SV, Ehrenfeld M, Holm PS, Nawroth R. Concepts in oncolytic adenovirus therapy. Int J Mol Sci. 2021;22:10522.","journal-title":"Int J Mol Sci."},{"key":"17650_CR108","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/2326-6066.CIR-16-0162","volume":"5","author":"AA Alkayyal","year":"2017","unstructured":"Alkayyal AA, Tai LH, Kennedy MA, et al. NK-cell recruitment is necessary for eradication of peritoneal Carcinomatosis with an IL12-expressing Maraba virus cellular vaccine. Cancer Immunol Res. 2017;5:211\u201321.","journal-title":"Cancer Immunol Res."},{"issue":"1265","key":"17650_CR109","first-page":"1275","volume":"73","author":"CJ Breitbach","year":"2013","unstructured":"Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 2013;73(1265):1275.","journal-title":"Cancer Res."},{"key":"17650_CR110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctrv.2011.04.002","volume":"38","author":"C Patriarca","year":"2012","unstructured":"Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev. 2012;38:68\u201375.","journal-title":"Cancer Treat Rev."},{"key":"17650_CR111","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000324667","volume":"34","author":"MA Str\u00f6hlein","year":"2011","unstructured":"Str\u00f6hlein MA, Lordick F, R\u00fcttinger D, et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I\/II trial. Onkologie. 2011;34:101\u20138.","journal-title":"Onkologie."},{"key":"17650_CR112","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","volume":"64","author":"RA Burga","year":"2015","unstructured":"Burga RA, Thorn M, Point GR, et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother. 2015;64:817\u201329.","journal-title":"Cancer Immunol Immunother."},{"key":"17650_CR113","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189\u201398.","journal-title":"Nat Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17650-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17650-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17650-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:02:25Z","timestamp":1754150545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17650-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":113,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["17650"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17650-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Dr. Dineen reports consulting fees, Oncoinvent < $5000. Dr. Wach has no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"During the preparation of this work, the authors used a large language model (ChatGPT V4o) to revise the manuscript text for coherence and clarity. After using this service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of AI-Assisted Technologies in the Writing Process"}}]}}